Abstracts

366 – Impact of the TKI Dasatinib on T-Cell Effector Functions in ART-Suppressed PWH (BCN04-DASA)

Background Dasatinib (DASA), a tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia, may help promote HIV-1 latency and reduce immune activation and senescence. However, DASA could impact T-cell effector functions by inhibition of TCR proximal kinases. Its impact on antigen-specific responses in people with HIV (PWH) is unclear. We evaluated the impact of low-dose…

914 – Area-Level Indicators as Proxies for Individual Socioeconomic Status in People With and Without HIV

Background Socioeconomic status (SES) is a key determinant of health outcomes for people with HIV (PWH). Many cohort studies collect individual-level measures of SES, while others (e.g., electronic health record-based cohorts) rely on area-level SES indicators as proxies. It is unclear which area-level indicators or geographic units best represent individual-level SES among PWH. Methods Using…

669 – HIV Reservoir Size Predicts Incident Carotid Plaque and Carotid IMT Progression in People With HIV

Background With expanded ART coverage, non–AIDS comorbidities, especially cardiovascular disease, are a major concern in people with HIV (PWH). Subclinical carotid atherosclerosis is a validated cardiovascular surrogate, yet systematic evaluation in PWH remains limited. HIV reservoirs have been linked to non–AIDS comorbidities. We tested whether reservoir measures associate with incident carotid plaque and intima–media thickness…

951 – Syndemic Factors and Viral Load Nonsuppression in People With HIV in Uganda: Latent Class Analysis

Background Despite widespread antiretroviral therapy (ART) coverage, viral load non-suppression (VLNS) remains a major challenge among people with HIV (PWH) in Uganda. Alcohol use, psychological distress, and condom use at last sex may compromise viral suppression, but their combined effects are understudied. Methods We analyzed data from the 2020–2021 Uganda Population-based HIV Impact Assessment (UPHIA),…

758 – Gut–Lung Axis Disruption in Long COVID Uncovered by Integrated Immuno-Epithelial-Microbial Profiling

Background The prevalence of long‑COVID (LC) is estimated to be >30%, and proposed pathogenetic pathways include dysbiosis, immune dysregulation, and tissue damage, yet integrated insights are still lacking. Using a multi‑layered approach, we assessed epithelial damage, systemic microbial translocation (MT), microbiome alterations, and δγ T-cell dysfunction along the gut–lung axis. Methods Unvaccinated, hospitalized COVID-19 patients…

778 – Inflammasome Activation and Hemophagocytic Lymphohistiocytosis Associate With Mortality in HIV-TB

Background Severe HIV-associated tuberculosis is frequently disseminated, and is the leading cause of mortality in people living with HIV globally. We hypothesized that high Mycobacterium tuberculosis (Mtb) disseminated load is associated with inflammasome activation resulting in hyperinflammation along the secondary hemophagocytic lymphohistiocytosis (HLH) spectrum and this predicts early mortality. Methods We analysed clinical data and frozen…

858 – Viral Suppression With Dolutegravir-Based Regimens in Children ≤5 Years Old in Southern Africa

Background Dolutegravir-based regimens (DBR) are currently the preferred first-line antiretroviral therapy (ART) for young children, but real-world data on outcomes remain limited. We evaluated virologic outcomes following DBR initiation or switch among children aged ≤5 years in Southern Africa. Methods We included children aged 0 to ≤5 years who initiated DBR or lopinavir/ritonavir(LPV/r)-based regimens, or…

618 – Cancer Survival Differences Persist Across Cancer Treatment Modalities Among People With HIV

Background The presence of HIV infection at the time of cancer diagnosis is associated with an increase in cancer-related mortality compared to cancer patients without HIV, likely driven by both sociodemographic differences among people with HIV (PWH) as well as the immune-modulatory impact of HIV on tumorigenesis. Our prior studies documenting survival differences among PWH…